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ABSTRACT 
 
Background: In addition to Human Leukocyte Antigens (HLA) compatibility, gene 
polymorphisms in cytokines might also be important in the quality of allogeneic im-
mune response. Objective: To evaluate the influence of HLA-DR matching and a 
number of cytokine gene polymorphisms on acute rejection after living-unrelated 
donor (LURD) kidney transplantation. Methods: A total of 42 renal transplants per-
formed at Hashemi Nejad Kidney Hospital (Tehran/Iran) and followed up for 3 
months post-transplantation were included. Using PCR-SSP, HLA-DR alleles (DR1-
18) of recipients and donors and gene polymorphisms in TNF-a, TGF-b1, IL-10, IL-
6, and IFN-g of recipients were determined. Results: Acute rejection was observed in 
11(26.2%) of renal recipients. The frequency of one and two HLA-DR mismatches 
in rejector group was 2(18.2%) and 9(81.8%) and in non-rejector group was 
13(41.9%) and 17(54.8%), respectively. HLA-DR incompatibility was not signifi-
cantly higher in rejector (1.82 0.40) compared with non-rejector (1.52 0.57) recipi-
ents (P=0.069) and more than half of non-rejectors had completely mismatched 
HLA-DR antigens with donors. Polymorphisms associated with the mentioned cyto-
kines had no correlation with acute rejection. Conclusion: The predictive value of 
HLA-DR mismatching for acute rejection is not as prominent in LURD kidney 
transplantation as in the cadaveric one. In addition, we failed to demonstrate an asso-
ciation between combined cytokine genotypes and HLA-DR matching with acute 
rejection. Further and more detailed immunogenetic investigations are required in 
order to have a better prediction of the transplant outcome. 
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INTRODUCTION 
 
Successful clinical transplantation depends in part on the immune processes that me-
diate rejection of the engrafted organ. Allograft acute rejection is the clinical mani-
festation of an uncontrolled alloimmune response directed against an allograft, in-
volving interactions between multiple cell types and a complex variety of factors in-
cluding Human Leukocyte Antigens (HLA), immunoregulatory mediators such as 
cytokines and growth factors, and the adequacy of immunosuppression. There is a 
correlation between HLA matching especially of HLA-DR type and decreased inci-
dence of clinical acute rejection episodes (1). In addition to recognition of specific 
non-self alloantigens, allograft rejection is stimulated by recognition of pre-
transplantation damage mostly ischemic and reperfusion injury leading to the up-
regulation of co-stimulatory, adhesion, and MHC class II molecules of donor tissue, 
followed by activation of specific T cells and production of cytokines and chemoki-
nes essential for evolution of an alloreactive immune response (2). 
Despite reduction in acute rejection incidence, it is still one of the major obstacles in 
achieving long-term allograft survival. It has been found in several studies that both 
the frequency and severity of acute rejection episodes may be a predisposing factor 
to reduced renal function and subsequent graft loss (3-5). Variations in both rejection 
rate and long-term outcome between patients with comparable immunosuppression 
and matching status have not been fully explained. 
Cytokines are important mediators in the regulation of immune response. A number 
of cytokine gene polymorphisms have been identified and their effects on the rate of 
acute rejection have been investigated. 
Tumor necrosis factor-α (TNF-α) is a pleotropic cytokine produced mainly by 
macrophages and T cells. It mediates cellular immune response and has a pro-
inflammatory nature. TNF-α stimulates macrophage function, increases HLA class II 
antigen expression, and is implicated in acute rejection. The polymorphism at posi-
tion -308 in the human TNF-α promoter region results in an A to G transition and a 
subsequent 6- to 7-fold increase in transcriptional activity. High producer genotypes 
were associated with acute rejection of kidney transplants (6). 
Transforming growth factor β1 (TGF-β1) is of particular interest because it promotes 
deposition of extracellular matrix and is shown to exert influence in many cellular 
growth and regulation events. TGF-β1 gene polymorphisms, located at positions 
+869 (T→C) and +915 (G→C) at codons 10 and 25, respectively, are in the signal 
sequence. High producer genotypes of TGF-β1 in donors (7) and recipients (8) were 
associated with kidney allograft rejection. 
Interleukin-10 (IL-10) is an important component of the anti-inflammatory cytokine 
network, suppressing gene expression and synthesis of pro-inflammatory cytokines. 
In the proximal promoter region of IL-10 three different inheritable haplotypes in-
volving three biallelic polymorphisms at -1082 (G→A), -819 (C→T), and -592 
(C→A) have been identified. In cardiac transplantation IL-10 high producer geno-
type has been associated with reduced incidence of cellular rejection (9). However, 
in renal transplantation, in combination with TNF-α high producer genotypes, it was 
associated with increased acute vascular rejection (10). 
Interleukin-6 (IL-6) is a multifunctional cytokine and mediates inflammatory and 
stress-induced responses. Within the promoter region of the IL-6 gene at position -
174, a C→G substitution is associated with a different transcription rate. A polymor-
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phism at position -174 of the donor IL-6 gene was associated with the incidence and 
severity of acute rejection (11). 
 Interferon- γ (IFN-γ) is a cytokine essential in the development and propagation of 
TH1-type immune response. A polymorphic dinucleotide (CA) marker has been de-
tected within the first intron of the IFN-γ gene at position +874 from the transcription 
start site. The CA microsatellite contains a SNP (T→A) at the 5′ end of the repeat, 
causing high, intermediate, and low producer genotypes. The high producer genotype 
was associated with acute rejection of kidney transplants (1). 
In the present study, we sought to determine the impact of HLA-DR matching and 
recipient cytokine gene polymorphisms on acute rejection after renal transplantation 
in a well-controlled living-unrelated donor (LURD) program. 
 
 
MATERIALS AND METHODS 
 
Graft outcome and acute rejection episode(s) in the first three months after transplan-
tation was determined in a total of 42 living-unrelated donor renal transplant recipi-
ents at Shahid Hashemi Nejad Hospital (Tehran/Iran). Rejection episodes were iden-
tified by an expert nephrology team based on clinical diagnostic criteria. HLA-DR 
matching and cytokine gene polymorphisms were compared between rejector and 
non-rejector groups. The immunosuppressive protocol was triple therapy of cyc-
losporine, azathioprine or mycophenolate mofetile, and prednisolone. 
DNA Extraction and Genotyping. Genomic DNA was obtained from fresh whole 
blood using a simple saturated NaCl based extraction technique (12). DNA quality 
and concentration was assessed by spectrophotometry at 260 and 280 nm. For HLA-
DR low resolution typing and detection of gene polymorphisms in TNF-α (-308  
A/G), TGF-β1 (+869 T/C, and +915 G/C), IL-10 (-1082 G/A, -819 C/T, and -592 
C/A), IL-6 (-174 C/G), and IFN-γ (+874 T/A), PCR-SSP based genotyping trays of 
One Lambda company (CA, USA) were used.  
Statistical Analysis. Association of rejection episodes with HLA-DR matching and 
high, intermediate, or low producer genotypes of each cytokine in rejector and non-
rejector groups were determined using student’s t test and contingency 2×2 table of 
Fisher’s exact test, respectively. P-values less than 0.05 were statistically significant. 
 
 
RESULTS 
 
Forty two living-unrelated donor kidney allograft recipients, including 29 (69%) men 
and 13 (31%) women were included. All recipients were engrafted for the first time 
and were not sensitized to HLA antigens (panel reactive antibody and WBC cross 
match negative). The majority of donors were younger than 35 years and organ dona-
tion was done under tight control of governmental health authorities. Acute rejection 
episode(s) observed in 11 (26.2%) of recipients in the early post transplant period.  
HLA-DR Matching and Acute Rejection. Frequency of HLA-DR mismatches in 
donor-recipient pairs is shown in table 1. HLA-DR incompatibility was not signifi-
cantly higher in rejector (1.82 0.40) than non-rejector (1.52 0.57) recipients 
(P=0.069). Furthermore, statistical analysis showed no significant association be-
tween HLA-DR mismatching and acute rejection (P=0.57). Interestingly, more than 
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half of the non-rejector recipients had completely mismatched HLA-DR antigens 
with their donors. 
 
Table 1. Frequency of HLA-DR mismatches in rejector  
and non-rejector groups 
 
HLA-DR Mismatches(MM) Rejectors (N=11) Non-rejectors (N=31) 
0 MM 0 (0.00%) 1 (3.23%) 
1 MM 2 (18.18%) 13 (41.93%) 
2 MM 9 (81.82%) 17 (54.84%) 
 
Cytokine Genotypes and Acute Rejection. Considering cytokine genotypes, kidney 
recipients were grouped into high, intermediate, and low producer genotypes (Table 2). 
TNF-α low producer genotype (G/G), IL-10 (GCC/ACC) and IFN-γ (T/A) interme-
diate producer genotypes, and TGF-β1 (T/C G/G) and IL-6 (G/G) high producer 
genotypes were dominant genotypes. No TNF-α high producer genotype (A/A) and 
TGF-β low producer genotypes (C/C G/C, C/C C/C, T/T C/C, and T/C C/C) were ob-
served. No association was found between each cytokine genotype and acute rejection. 
 
Table 2. Frequency of cytokine genotypes in rejector and 
non-rejector groups 
Cytokine Genotype (Phenotype) 
Rejectors 
(N=11) 
Non-rejectors 
(N=31) 
TNF-αa G/G (L) 8 (72.72%) 24 (77.42%) 
 G/A (H) 3 (27.28%) 7 (22.58%) 
 A/A (H) 0 (0.00%) 0 (0.00%) 
TGF-β1b T/T G/G (H) 1 (9.09%) 8 (25.80%) 
 T/C G/G (H) 6 (54.54%) 11 (35.48%) 
 T/C G/C (I) 2 (18.18%) 6 (19.35%) 
 C/C G/G (I) 1 (9.09%) 5 (16.13%) 
 T/T G/C (I) 1 (9.09%) 1 (3.23%) 
 C/C G/C (L) 0 (0.00%) 0 (0.00%) 
 C/C C/C (L) 0 (0.00%) 0 (0.00%) 
 T/T C/C (L) 0 (0.00%) 0 (0.00%) 
 T/C C/C (L) 0 (0.00%) 0 (0.00%) 
IL-10c GCC/GCC (H) 3 (27.27%) 4 (12.90%) 
 GCC/ACC (I) 2 (18.18%) 12 (38.70%) 
 GCC/ATA (I) 3 (27.27%) 7 (22.58%) 
 ACC/ACC (L) 1 (9.09%) 2 (6.45%) 
 ACC/ATA (L) 1 (9.09%) 4 (12.90%) 
 ATA/ATA (L) 1 (9.09%) 2 (6.45%) 
IL-6d G/G (H) 7 (63.64%) 18 (58.06%) 
 G/C (H) 3(27.27%) 12 (38.70%) 
 C/C (L) 1 (9.09%) 1 (3.23%) 
IFN-γe T/T (H) 3 (27.27%) 5 (16.13%) 
 T/A (I) 6 (54.54%) 20 (64.52%) 
 A/A (L) 2 (18.18%) 6 (19.35%) 
H: High, I: Intermediate, L: Low  
a P-value = 1.000, b P-value = 1.000, c P-value = 0.504, d P-value = 0.460, e P-value = 0.717 
 
 
Association between Combination of HLA-DR Matching and Cytokine Geno-
types and Acute Rejection. No significant association was found between the oc-
currence of acute rejection episode(s) with the combination of HLA-DR matching 
and each cytokine genotype (Table 3). 
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Table 3. Frequency of cytokine genotypes and HLA-DR mismatches in  
rejector and non-rejector groups 
  
Nonrejectors ( N=31)  Rejectors (N=11)      
2 MM  1 MM  0 MM  2 MM  1 MM  0 MM      
17  13  1  9  2  0  Production    
12(70.59%)  11(84.62%)  1(100%)  8 (88.89%)  0 (0.00%)  0 (0.00%)  L  
5 (29.41%)  2 (15.38%)  0 (0.00%)  1 (11.11%)  2 (100%)  0 (0.00%)  H  
TNF-α  
0 (0.00%)  0 (0.00%)  0 (0.00%)  0 (0.00%)  0 (0.00%)  0 (0.00%)  L  
5 (29.41%)  7 (53.85%)  0 (0.00%)  3 (33.33%)  1(50%)  0 (0.00%)  I  
12(70.59%)  6 (46.15%)  1 (100%)  6 (66.67%)  1 (50%)  0 (0.00%)  H  
TGF-β1  
3 (17.65%)  5 (38.46%)  0 (0.00%)  3 (33.33%)  0 (0.00%)  0 (0.00%)  L  
11(64.70%)  7 (53.85%)  1 (100%)  4 (44.44%)  1 (50%)  0 (0.00%)  I  
3 (17.65%)  1 (7.69%)  0 (0.00%)  2 (22.22%)  1 (50%)  0 (0.00%)  H  
IL-10  
0 (0.00%)  1 (7.69%)  0 (0.00%)  1 (11.11%)  0 (0.00%)  0 (0.00%)  L  
17(100%)  12(92.31%)  1 (100%)  8 (88.89%)  2 (100%)  0(0.00%)  H  IL-6  
3 (17.65%)  3 (23.08%)  0 (0.00%)  2 (22.22%)  0 (0.00%)  0 (0.00%)  L  
13(76.47%)  6 (46.15%)  1 (100%)  4 (44.44%)  2 (100%)  0 (0.00%)  I  
1 (5.88%)  4 (30.77%)  0 (0.00%)  3 (33.33%)  0(0.00%)  0 (0.00%)  H  
IFN-γ  
H: High, I: Intermediate, L: Low 
 
 
DISCUSSION 
 
Currently, there are some identified variables that are considered in organ allocation 
algorithms and standardized therapeutic protocols which may be useful to improve 
long-term renal allograft survival. These factors include the degree of HLA matching 
especially in DR locus (1, 13), ischemic-reperfusion injury, and the immunosuppres-
sive regimen (14, 15). Recently the recipient immune responsiveness is also consid-
ered (16). Inter-individual differences in immune responsiveness can be attributable 
to genetic variability in the coding and regulatory regions of immune system media-
tors especially cytokines (17). In spite of several studies, the exact role of cytokine 
gene polymorphism in transplant outcome remains controversial (18), with some 
groups showing a correlation (19, 10) and others not (13). 
One must keep in mind that the immune response against graft tissue takes place un-
der an immunosuppressive situation which can influence most aspects of the immune 
response including cellular activation and gene expression, making the therapeutic 
regimen a significant variable. For instance, in the study of Marshall et al. (13) cyc-
losporine, azathioprine, and prednisone were used. They didn’t find any association 
between cytokine gene polymorphisms and the occurrence or severity of acute rejec-
tion. On the other hand, monotherapy regimen with cyclosporine was used in the 
study of Sankaran et al. (10). They found that TNF-α high producer/IL-10 high pro-
ducer genotypes have the worst prognosis, but TNF-α low producer/IL-10 low pro-
ducer genotypes are protective, suggesting that cyclosporine alone does not com-
pletely block cytokine production. 
Recognition phase is an important step in the development of immune response. This 
is a fact that cytokine gene expression polymorphisms control the production of cy-
tokines only when the source cells are activated. The most important antigens in al-
loantigen-dependent recognition pathway are HLA antigens and it has been sug-
gested that the impact of cytokine genotype may be influenced by the degree of im-
mune activation initiated by an HLA class II mismatch (13). In addition, recipient 
immune system is also stimulated via alloantigen-independent recognition pathways, 
especially by ischemic-reperfusion injury which besides parenchymal damage, in-
creases the immunogenecity of allograft. This type of injury is important in cadaveric 
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renal transplantation, and is not crucial in live donors (2). Therefore, the source of 
kidney is important and studies on cadaveric kidney transplantation yields different 
results from living ones. 
As the heart and the lung are considered to be more immunogenic than kidney, it is 
conceivable that the impact of some of these polymorphisms is only manifested 
when the immune system is maximally activated (13). In other words, controversial 
findings may result from tissue-specific effects of particular organs or tissues. 
Our population study was LURD allograft kidney recipients and cyclosporine, 
azathioprine/mycophenolate, and prednisolone were used. There was no association 
between HLA-DR matching and cytokine gene polymorphisms, and the occurrence 
of acute rejection. It is noteworthy that in more than 50% of non-rejector recipients 
full mismatched HLA-DR status was observed. As transplanted organs taken from 
live donors have undergone minimal pre-transplantation stresses, alloantigen-
independent stimulation was reduced; therefore, triple immunosuppressive regimen 
could overcome alloantigen-dependent stimulation of the recipient immune system. 
Although our sample size was limited and clinical criteria were used to prove acute 
rejection; however, our findings are informative as LURD kidney transplantation is 
not widely used throughout the world, and there is tendency toward using this 
method in developed countries (20). 
In conclusion, the predictive value of HLA-DR mismatching for acute rejection is 
not as prominent in LURD kidney transplantation as in the cadaveric one, however, 
there is no doubt about the influence of HLA compatibility on allograft survival. In 
addition, we failed to demonstrate an association between combined cytokine geno-
types and HLA-DR matching with acute rejection. Further and more detailed immu-
nogenetic investigations are required in order to have a better prediction of the trans-
plant outcome. 
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